Top

Published in:

01-01-2018 | Topic Review

Clinical implications of in silico mathematical modeling for glioblastoma: a critical review

Authors: Maria Protopapa, Anna Zygogianni, Georgios S. Stamatakos, Christos Antypas, Christina Armpilia, Nikolaos K. Uzunoglu, Vassilis Kouloulias

Published in: Journal of Neuro-Oncology | Issue 1/2018

Abstract

Glioblastoma remains a clinical challenge in spite of years of extensive research. Novel approaches are needed in order to integrate the existing knowledge. This is the potential role of mathematical oncology. This paper reviews mathematical models on glioblastoma from the clinical doctor’s point of view, with focus on 3D modeling approaches of radiation response of in vivo glioblastomas based on contemporary imaging techniques. As these models aim to provide a clinically useful tool in the era of personalized medicine, the integration of the latest advances in molecular and imaging science and in clinical practice by the in silico models is crucial for their clinical relevance. Our aim is to indicate areas of GBM research that have not yet been addressed by in silico models and to point out evidence that has come up from in silico experiments, which may be worth considering in the clinic. This review examines how close these models have come in predicting the outcome of treatment protocols and in shaping the future of radiotherapy treatments.

Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G (2014) High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:93–101. doi:10.1093/annonc/mdu050 CrossRef

Ostrom QT, Gittleman H, Fulop J et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 17:iv1–iv62. doi:10.1093/neuonc/nov189 CrossRefPubMedPubMedCentral

Kelly PJ (1993) Computed tomography and histologic limits in glial neoplasms: tumor types and selection for volumetric resection. Surg Neurol 39(6):458–465. http://www.ncbi.nlm.nih.gov/pubmed/8390726

Muller C, Holtschmidt J, Auer M et al (2014) Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med 6(247):247ra101–247ra101. doi:10.1126/scitranslmed.3009095 CrossRefPubMed

Gil-Salú JL, Román P, Benítez E, Maestro E, Pérez-Requena J, López-Escobar M (2004) [Survival analysis following the addition of temozolomide to surgery and radiotherapy in patients with glioblastoma multiforme]. Neurocirugia 15(2):144–150. http://www.ncbi.nlm.nih.gov/pubmed/15159792

Koshy M, Villano JL, Dolecek TA et al (2012) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107(1):207–212. doi:10.1007/s11060-011-0738-7 CrossRefPubMed

Young RM, Jamshidi A, Davis G, Sherman JH (2015) Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med. doi:10.3978/j.issn.2305-5839.2015.05.10 PubMedPubMedCentral

Gatenby RA, Maini PK (2003) Mathematical oncology: cancer summed up. Nature 421(6921):321–321. doi:10.1038/421321a CrossRefPubMed

Marcu LG, Harriss-Phillips WM (2012) In silico modelling of treatment-induced tumour cell kill: developments and advances. Comput Math Methods Med 2012:960256. doi:10.1155/2012/960256 CrossRefPubMedPubMedCentral

10.

Swanson KR, Alvord EC, Murray JD (2002) Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy. Br J Cancer 86(1):14–18. doi:10.1038/sj.bjc.6600021 CrossRefPubMedPubMedCentral

11.

Swanson KR, Harpold HLP, Peacock DL et al (2008) Velocity of radial expansion of contrast-enhancing gliomas and the effectiveness of radiotherapy in individual patients: a proof of principle. Clin Oncol 20(4):301–308. doi:10.1016/j.clon.2008.01.006 CrossRef

12.

Harpold HLP, Alvord EC, Swanson KR (2007) The evolution of mathematical modeling of glioma proliferation and invasion. J Neuropathol Exp Neurol 66(1):1–9. doi:10.1097/nen.0b013e31802d9000 CrossRefPubMed

13.

Swanson KR, Alvord EC, Murray JD (2000) A quantitative model for differential motility of gliomas in grey and white matter. Cell Prolif 33(5):317–329. http://www.ncbi.nlm.nih.gov/pubmed/11063134. Accessed 12 March 2017

14.

Collins DL, Zijdenbos AP, Kollokian V et al (1998) Design and construction of a realistic digital brain phantom. IEEE Trans Med Imaging 17(3):463–468. doi:10.1109/42.712135 CrossRefPubMed

15.

Mabray MC, Barajas RF, Cha S, Cha S (2015) Modern brain tumor imaging. Brain Tumor Res Treat 3(1):8–23. doi:10.14791/btrt.2015.3.1.8 CrossRefPubMedPubMedCentral

16.

Silbergeld DL, Chicoine MR (1997) Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 86(3):525–531. doi:10.3171/jns.1997.86.3.0525 CrossRefPubMed

17.

Wilson CB (1992) Glioblastoma: the past, the present, and the future. Clin Neurosurg 38:32–48. https://www.ncbi.nlm.nih.gov/pubmed/1311227

18.

Swanson KR, Rostomily RC, Alvord EC (2008) A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle. Br J Cancer 98:113–119. doi:10.1038/sj.bjc.6604125 CrossRefPubMed

19.

Wang C, Rochhill J, Mrugala M et al (2009) Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel bio-mathematical model. Cancer Res 69(23):9133–9140. doi:10.1158/0008-5472.CAN-08-3863 CrossRefPubMedPubMedCentral

20.

Rockne R, Alvord EC, Rockhill JK, Swanson KR (2009) A mathematical model for brain tumor response to radiation therapy. J Math Biol 58(4–5):561–578. doi:10.1007/s00285-008-0219-6 CrossRefPubMed

21.

Rockne R, Rochhill J, Mrugala M et al (2010) Predicting efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach. Phys Med Biol 55(12):3271–3285CrossRefPubMedPubMedCentral

22.

Baldock AL, Ahn S, Rockne R et al (2014) Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomas. PLoS ONE 9(10):7–9. doi:10.1371/journal.pone.0099057 CrossRef

23.

Roniotis A, Marias K, Sakkalis V, Manikis GC, Zervakis M (2012) Simulating radiotherapy effect in high-grade glioma by using diffusive modeling and brain atlases. J Biomed Biotechnol. doi:10.1155/2012/715812 PubMedPubMedCentral

24.

Holdsworth CH, Corwin D, Stewart RD et al (2012) Adaptive IMRT using a multiobjective evolutionary algorithm integrated with a diffusion-invasion model of glioblastoma. Phys Med Biol 57(24):8271–8283. doi:10.1088/0031-9155/57/24/8271 CrossRefPubMedPubMedCentral

25.

Unkelbach J, Menze BH, Konukoglu E, Dittmann F, Ayache N, Shih HA (2014) Radiotherapy planning for glioblastoma based on a tumor growth model: implications for spatial dose redistribution. Phys Med Biol 59(3):771–789. doi:10.1088/0031-9155/59/3/771 CrossRefPubMed

26.

Neal ML, Trister AD, Cloke T et al (2013) Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patient-specific response metric. PLoS ONE. doi:10.1371/journal.pone.0051951

27.

Neal ML, Trister AD, Ahn S et al (2013) Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression. Cancer Res 73(10):2976–2986. doi:10.1158/0008-5472.CAN-12-3588 CrossRefPubMedPubMedCentral

28.

Corwin D, Holdsworth C, Rockne RC et al (2013) Toward patient-specific, biologically optimized radiation therapy plans for the treatment of glioblastoma. PLoS ONE. doi:10.1371/journal.pone.0079115 PubMedPubMedCentral

29.

Zhao Y, Adjei AA (2015) Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist 20(6):660–673. doi:10.1634/theoncologist.2014-0465 CrossRefPubMedPubMedCentral

30.

Szeto MD, Chakraborty G, Hadley J et al (2009) Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res 69(10):4502–4509. doi:10.1158/0008-5472.CAN-08-3884 CrossRefPubMedPubMedCentral

31.

Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 3708370(20):699–708. doi:10.1056/NEJMoa1308573 CrossRef

32.

Chinot OL, Wick W, Cloughesy T (2014) Bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(21):2049. http://www.ncbi.nlm.nih.gov/pubmed/24860870

33.

Hawkins-Daarud A, Rockne RC, Anderson ARA, Swanson KR (2013) Modeling tumor-associated edema in gliomas during anti-angiogenic therapy and its impact on imageable tumor. Front Oncol 3(April):66. doi:10.3389/fonc.2013.00066 PubMedPubMedCentral

34.

Saut O, Lagaert JB, Colin T, Fathallah-Shaykh HM (2014) A multilayer grow-or-go model for GBM: effects of invasive cells and anti-angiogenesis on growth. Bull Math Biol 76(9):2306–2333. doi:10.1007/s11538-014-0007-y CrossRefPubMed

35.

Gerlee P, Nelander S (2012) The impact of phenotypic switching on glioblastoma growth and invasion. PLoS Comput Biol. doi:10.1371/journal.pcbi.1002556 PubMedPubMedCentral

36.

Greene GM, Hitchon PW, Schelper RL, Yuh W, Dyste GN (1989) Diagnostic yield in CT-guided stereotactic biopsy of gliomas. J Neurosurg 71(4):494–497. doi:10.3171/jns.1989.71.4.0494 CrossRefPubMed

37.

Hatzikirou H, Basanta D, Simon M, Schaller K, Deutsch A (2012) “Go or Grow”: the key to the emergence of invasion in tumour progression? Math Med Biol 29(1):49–65. doi:10.1093/imammb/dqq011 CrossRefPubMed

38.

Colombo MC, Giverso C, Faggiano E, Boffano C, Acerbi F, Ciarletta P (2015) Towards the personalized treatment of glioblastoma: integrating patient-specific clinical data in a continuous mechanical model. PLoS ONE 10(7):1–23. doi:10.1371/journal.pone.0132887 CrossRef

39.

Düchting W, Ulmer W, Lehrig R, Ginsberg T, Dedeleit E (1992) Computer simulation and modelling of tumor spheroid growth and their relevance for optimization of fractionated radiotherapy. Strahlenther Onkol 168(6):354–360. http://www.ncbi.nlm.nih.gov/pubmed/1320297. Accessed 13 March 2017

40.

Wasserman R, Acharya R, Sibata C, Shin KH (1996) A patient-specific in vivo tumor model. Math Biosci 136(2):111–140. doi:10.1016/0025-5564(96)00045-4 CrossRefPubMed

41.

Kansal AR, Torquato S, Harsh GR, Chiocca EA, Deisboeck TS (2000) Simulated brain tumor growth dynamics using a three-dimensional cellular automaton. J Theor Biol 203(4):367–382. doi:10.1006/jtbi.2000.2000 CrossRefPubMed

42.

Kansal AR, Torquato S, Harsh IV GR, Chiocca EA, Deisboeck TS (2000) Cellular automaton of idealized brain tumor growth dynamics. Biosystems 55:119–127. doi:10.1016/S0303-2647(99)00089-1 CrossRefPubMed

43.

Duchting W, Ginsberg T, Ulmer W (1995) Chapter 7: Biomathematical engineering of cell renewal systems: modeling of radiogenic responses induced by fractionated irradiation in malignant and normal tissue. Stem Cells 13(S1):301–306. doi:10.1002/stem.5530130737 CrossRefPubMed

44.

Düchting W, Ginsberg T, Ulmerb W (1995) Modeling of radiogenic responses induced by fractionated irradiation in malignant and normal tissue. Stem Cells 13:301–306CrossRefPubMed

45.

Dionysiou DD, Stamatakos GS, Uzunoglu NK, Nikita KS, Marioli A (2004) A four-dimensional simulation model of tumour response to radiotherapy in vivo: parametric validation considering radiosensitivity, genetic profile and fractionation. J Theor Biol 230(1):1–20. doi:10.1016/j.jtbi.2004.03.024 CrossRefPubMed

46.

Dionysiou DD, Peristeris T, Stamatakos GS, Nikita KS, Uzunoglu NK (2004) The genetic profile of a tumor as a determinant of its response to radiotherapy: a computer simulation of two different radiotherapeutic schemes. In: Proceedings of the 26th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, vols 1–7. 26(gap 2):3035–3038

47.

Dionysiou DD, Stamatakos GS, Gintides D, Uzunoglu N, Kyriaki K (2008) Critical parameters determining standard radiotherapy treatment outcome for glioblastoma multiforme: a computer simulation. Open Biomed Eng J 2(v):43–51. doi:10.2174/1874120700802010043 CrossRefPubMedPubMedCentral

48.

Marias K, Dionysiou D, Sakkalis V et al (2011) Clinically driven design of multi-scale cancer models: the ContraCancrum project paradigm. Interface Focus 1(3):450–461. doi:10.1098/rsfs.2010.0037 CrossRefPubMedPubMedCentral

49.

May CP, Kolokotroni E, Stamatakos GS, Büchler P (2011) Coupling biomechanics to a cellular level model: an approach to patient-specific image driven multi-scale and multi-physics tumor simulation. Prog Biophys Mol Biol 107(1):193–199. doi:10.1016/j.pbiomolbio.2011.06.007 CrossRefPubMed

50.

Baldock AL, Rockne RC, Boone AD et al (2013) From patient-specific mathematical neuro-oncology to precision medicine. Front Oncol 3(April):1–11. doi:10.3389/fonc.2013.00062

51.

Dionysiou DD, Stamatakos GS (2006) Applying a 4D multiscale in vivo tumor growth model to the exploration of radiotherapy scheduling: the effects of weekend treatment gaps and p53 gene status on the response of fast growing solid tumors. Cancer Inform 2:113–121CrossRef

52.

Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110. doi:10.1016/j.ccr.2009.12.020 CrossRefPubMedPubMedCentral

53.

Hegi ME, Diserens A-C, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. doi:10.1056/NEJMoa043331 CrossRefPubMed

54.

Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloëguen Y, Cloughesy TF (2013) Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep 13:347. doi:10.1007/s11910-013-0347-2 CrossRefPubMedPubMedCentral

55.

Weller M, Stupp R, Reifenberger G et al (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6(1):39–51. doi:10.1038/nrneurol.2009.197 CrossRefPubMed

56.

Sathyan P, Zinn PO, Marisetty AL et al (2015) Mir-21-Sox2 axis delineates glioblastoma subtypes with prognostic impact. J Neurosci 35(45):15097–15112. doi:10.1523/JNEUROSCI.1265-15.2015 CrossRefPubMedPubMedCentral

57.

Cihoric N, Tsikkinis A, Minniti G et al (2017) Current status and perspectives of interventional clinical trials for glioblastoma—analysis of ClinicalTrials.gov. Radiat Oncol 12(1):1. doi:10.1186/s13014-016-0740-5 CrossRefPubMedPubMedCentral

58.

Pedicini P, Fiorentino A, Simeon V et al (2014) Clinical radiobiology of glioblastoma multiforme. Strahlentherapie Onkol 190(10):925–932. doi:10.1007/s00066-014-0638-9 CrossRef

59.

Arvold ND, Reardon DA (2014) Treatment options and outcomes for glioblastoma in the elderly patient. Clin Interv Aging 9:357–367. doi:10.2147/CIA.S44259 PubMedPubMedCentral

60.

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330 CrossRefPubMed

61.

Weller M, van den Bent M, Hopkins K et al (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15(9):e395–e403. doi:10.1016/S1470-2045(14)70011-7 CrossRefPubMed

62.

Hawkins-Daarud A, Rockne R, Corwin D, Anderson ARA, Kinahan P, Swanson KR (2015) In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma. J Royal Soc Interface 12(109):20150388. doi:10.1098/rsif.2015.0388 CrossRef

63.

Antipas VP, Stamatakos GS, Uzunoglu NK, Dionysiou DD, Dale RG (2004) A spatio-temporal simulation model of the response of solid tumours to radiotherapy in vivo: parametric validation concerning oxygen enhancement ratio and cell cycle duration. Phys Med Biol 49(8):1485–1504CrossRefPubMed

Title: Clinical implications of in silico mathematical modeling for glioblastoma: a critical review
Authors: Maria Protopapa
Anna Zygogianni
Georgios S. Stamatakos
Christos Antypas
Christina Armpilia
Nikolaos K. Uzunoglu
Vassilis Kouloulias
Publication date: 01-01-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2650-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Clinical implications of in silico mathematical modeling for glioblastoma: a critical review

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Preoperative relative cerebral blood volume analysis in gliomas predicts survival and mitigates risk of biopsy sampling error

Atypical meningioma: progression-free survival in 161 cases treated at our institution with surgery versus surgery and radiotherapy

MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma

A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker

Current and emerging treatment strategies for children with progressive chiasmatic-hypothalamic glioma diagnosed as infants: a web-based survey

Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma